Abstract
Purpose
Pediatric low-grade gliomas are the most frequent brain tumors in children. The standard approach for symptomatic unresectable tumors is chemotherapy. Recently, key molecular alterations/pathways have been identified and targeted drugs developed and tested in clinical trials. We describe our institutional experience with MAPK pathway targeted therapy.
Methods
We retrospectively reviewed the medical reports of 23 patients diagnosed with PLGG and treated with either trametinib or dabrafenib at Hospital Sant Joan de Dèu (Barcelona, Spain). Patients with neurofibromatosis were excluded. Objective response rate (ORR) and disease control rate (DCR) were determined using the Response Assessment in Pediatric Neuro-Oncology criteria in low-grade glioma. ORR was defined as the proportion of patients with the best overall response including complete remission (CR) or partial remission (PR). DCR was the sum of the CR, PR, and stable disease (SD) rates.
Results
ORR with trametinib was 0% (95% CI, 0%–23.2%) and DCR was 78.6% (95% CI, 49.2%–95.3%). Eleven patients had SD and three patients presented PD. ORR with dabrafenib was 41.7% (95% CI, 16.5%–71.4%), including four CR and one patient with PR. DCR with dabrafenib was 100% (95% CI, 73.5%–100%); there were seven SD and none PD. Treatment was well tolerated. Only three patients, on trametinib, presented grade 3 adverse effects: leukocytoclastic vasculitis, cheilitis, and bone infection.
Conclusions
Our experience adds to the growing data about the efficacy and tolerability of targeted therapy in patients with PLGG. When present, toxicity is mainly mild-moderate and transient. Ongoing prospective clinical trials are trying to address if its use should be advanced to first-line therapy.
Similar content being viewed by others
References
Chen YH, Gutmann DH (2014) The molecular and cell biology of pediatric low-grade gliomas. Oncogene 33(16):2019–2026. https://doi.org/10.1038/onc.2013.148
Bandopadhayay P, Bergthold G, London WB, Goumnerova LC, Morales La Madrid A, Marcus KJ, Guo D, Ullrich NJ, Robison NJ, Chi SN, Beroukhim R, Kieran MW, Manley PE (2014) Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer 61(7):1173–1179
Krishnatry R, Zhukova N, Guerreiro Stucklin AS, Pole JD, Mistry M, Fried I, Ramaswamy V, Bartels U, Huang A, Laperriere N, Dirks P, Nathan PC, Greenberg M, Malkin D, Hawkins C, Bandopadhayay P, Kieran MW, Manley PE, Bouffet E, Tabori U (2016) Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study. Cancer. 122(8):1261–1269
Kandels D, Pietsch T, Bison B, Warmuth-Metz M, Thomale UW, Kortmann RD, Timmermann B, Hernáiz Driever P, Witt O, Schmidt R, Gnekow AK (2020) Loss of efficacy of subsequent nonsurgical therapy after primary treatment failure in pediatric low-grade glioma patients—report from the German SIOP-LGG 2004 cohort. Int J Cancer 147:3471–3489
Jones DTW, Kieran MW, Bouffet E, Alexandrescu S, Bandopadhayay P, Bornhorst M, Ellison D, Fangusaro J, Fisher MJ, Foreman N, Fouladi M, Hargrave D, Hawkins C, Jabado N, Massimino M, Mueller S, Perilongo G, Schouten van Meeteren AYN, Tabori U, Warren K, Waanders AJ, Walker D, Weiss W, Witt O, Wright K, Zhu Y, Bowers DC, Pfister SM, Packer RJ (2018) Pediatric low-grade gliomas: next biologically driven steps. Neuro-Oncology 20(2):160–173
Penman CL, Faulkner C, Lowis SP, Kurian KM (2015) Current understanding of BRAF alterations in diagnosis, prognosis and therapeutic targeting in paediatric low grade gliomas. Front Oncol 5(54):1–10
Roth JJ, Santi M, Pollock AN, Harding BN, Rorke-adams LB, Tooke LS et al (2015) Chromosome band 7q34 deletions resulting in KIAA1549-BRAF and FAM131B-BRAF fusions in pediatric low-grade gliomas. Brain Pathol 25(2):182–192
Shin CH, Grossmann AH, Holmen SL, Robinson JP (2015) The BRAF kinase domain promotes the development of gliomas in vivo. Genes Cancer 6(1–2):9–18
Basto D, Trovisco V, Lopes JM, Martins A, Pardal F, Soares P et al (2005) Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol 109(2):207–210
Lassaletta A, Zapotocky M, Mistry M, Ramaswamy V, Honnorat M, Krishnatry R, Guerreiro Stucklin A, Zhukova N, Arnoldo A, Ryall S, Ling C, McKeown T, Loukides J, Cruz O, de Torres C, Ho CY, Packer RJ, Tatevossian R, Qaddoumi I, Harreld JH, Dalton JD, Mulcahy-Levy J, Foreman N, Karajannis MA, Wang S, Snuderl M, Nageswara Rao A, Giannini C, Kieran M, Ligon KL, Garre ML, Nozza P, Mascelli S, Raso A, Mueller S, Nicolaides T, Silva K, Perbet R, Vasiljevic A, Faure Conter C, Frappaz D, Leary S, Crane C, Chan A, Ng HK, Shi ZF, Mao Y, Finch E, Eisenstat D, Wilson B, Carret AS, Hauser P, Sumerauer D, Krskova L, Larouche V, Fleming A, Zelcer S, Jabado N, Rutka JT, Dirks P, Taylor MD, Chen S, Bartels U, Huang A, Ellison DW, Bouffet E, Hawkins C, Tabori U (2017) Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol 35(25):2934–2941
Mistry M, Zhukova N, Merico D, Rakopoulos P, Krishnatry R, Shago M, Stavropoulos J, Alon N, Pole JD, Ray PN, Navickiene V, Mangerel J, Remke M, Buczkowicz P, Ramaswamy V, Guerreiro Stucklin A, Li M, Young EJ, Zhang C, Castelo-Branco P, Bakry D, Laughlin S, Shlien A, Chan J, Ligon KL, Rutka JT, Dirks PB, Taylor MD, Greenberg M, Malkin D, Huang A, Bouffet E, Hawkins CE, Tabori U (2015) BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol 33(9):1015–1022
Kondyli M, Larouche V, Saint-Martin C, Ellezam B, Pouliot L, Sinnett D et al (2018) Trametinib for progressive pediatric low-grade gliomas. J Neuro-Oncol 140(2):435–444. https://doi.org/10.1007/s11060-018-2971-9
Nicolaides T, Nazemi KJ, Crawford J, Kilburn L, Minturn J, Gajjar A, Gauvain K, Leary S, Dhall G, Aboian M, Robinson G, Long-Boyle J, Wang H, Molinaro AM, Mueller S, Prados M (2020) Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget. 11(21):1942–1952
Hargrave DR, Bouffet E, Tabori U, Broniscer A, Cohen KJ, Hansford JR, Geoerger B, Hingorani P, Dunkel IJ, Russo MW, Tseng L, Dasgupta K, Gasal E, Whitlock JA, Kieran MW (2019) Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation–positive relapsed or refractory low-grade glioma: results from a phase I/IIa study. Clin Cancer Res 25(24):7303–7311
Perreault S, Larouche V, Tabori U, Hawkin C, Lippé S, Ellezam B et al (2019) A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. BMC Cancer 19(1):1–9
Manoharan N, Choi J, Chordas C, Zimmerman MA, Scully J, Clymer J et al (2020) Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma. J Neuro-Oncol 149(2):253–262. https://doi.org/10.1007/s11060-020-03592-8
Fangusaro J, Witt O, Hernáiz Driever P, Bag AK, de Blank P, Kadom N et al (2020) Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol 21(6):e305–e316. https://doi.org/10.1016/S1470-2045(20)30064-4
Nobre L, Zapotocky M, Ramaswamy V, Ryall S, Bennet J, Alderete D et al (2020) Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition. JCO Precis Oncol 4(4):561–571
Selt F, van Tilburg CM, Bison B, Sievers P, Harting I, Ecker J et al (2020) Response to trametinib treatment in progressive pediatric low-grade glioma patients. J Neuro-Oncol 149(3):499–510. https://doi.org/10.1007/s11060-020-03640-3
Menzies AM, Long GV (2014) Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin Cancer Res 20(8):2035–2043
Cebollero A, Puértolas T, Pajares I, Calera L, Antón A (2016) Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma. Mol Clin Oncol 5(4):458–462
Welsh SJ, Corrie PG (2015) Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol 7(2):122–136
Lacroix J, Wang B (2017) Prospective case series of cutaneous adverse effects associated with dabrafenib and trametinib. J Cutan Med Surg 21(1):54–59
Hauschild A, Grob J, Demidov LV, Jouary T, Gutzmer R, Millward M et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358–365. https://doi.org/10.1016/S0140-6736(12)60868-X
Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS et al (2012) Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol 67(6):1265–1272. https://doi.org/10.1016/j.jaad.2012.04.008
Peng L, Wang Y, Hong Y, Ye X, Shi P, Zhang J, Zhao Q (2017) Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis. Oncotarget. 8(47):83280–83291
Atkinson V, Long GV, Menzies AM, McArthur G, Carlino MS, Millward M, Roberts-Thomson R, Brady B, Kefford R, Haydon A, Cebon J (2016) Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists. Asia Pac J Clin Oncol 12:5–12
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty D (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372(1):30–39
Stjepanovic N, Velazquez-Martin JP, Bedard PL (2016) Ocular toxicities of MEK inhibitors and other targeted therapies. Ann Oncol 27(6):998–1005. https://doi.org/10.1093/annonc/mdw100
Olow A, Mueller S, Yang X, Hashizume R, Meyerowitz J, Weiss W, Resnick AC, Waanders AJ, Stalpers LJA, Berger MS, Gupta N, James CD, Petritsch CK, Haas-Kogan DA (2016) BRAF status in personalizing treatment approaches for pediatric gliomas. Clin Cancer Res 22(21):5312–5321
Drobysheva A, Klesse LJ, Bowers DC (2017) Targeted MAPK pathway inhibitors in patients with disseminated pilocytic astrocytomas. J Natl Compr Cancer Netw 15(8):978–982
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflicts of interest to declare that are relevant to the content of this article.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
ESM 1
(PPTX 52 kb)
Rights and permissions
About this article
Cite this article
Pérez, J.P.M., Muchart, J., López, V.SM. et al. Targeted therapy for pediatric low-grade glioma. Childs Nerv Syst 37, 2511–2520 (2021). https://doi.org/10.1007/s00381-021-05138-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00381-021-05138-3